A Resurrection of 7-MEOTA: A Comparison with Tacrine

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10139641" target="_blank" >RIV/00179906:_____/13:10139641 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/67985823:_____/13:00397542 RIV/60162694:G44__/13:43874805 RIV/00216208:11160/13:10139641

Výsledek na webu

<a href="http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=24093535.ui" target="_blank" >http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=24093535.ui</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

A Resurrection of 7-MEOTA: A Comparison with Tacrine

Popis výsledku v původním jazyce

Alzheimer's disease (AD) is a progressive neurodegenerative dementia which currently represents one of the biggest threats for the human kind. The cure is still unknown and various hypotheses (cholinergic, amyloidal, oxidative, vascular etc.) are investigated in order to understand the pathophysiology of the disease and on this basis find an effective treatment. Tacrine, the first approved drug for the AD disease treatment, has been reported to be a multitargeted drug, however it was withdrawn from themarket particularly due to its hepatotoxicity. Its derivative 7-methoxytacrine (7-MEOTA) probably due to the different metabolization does not exert this side effect. The aim of our study was to compare these two cholinesterase inhibitors from various, mainly cholinergic, points of view relevant for a potential AD drug. We found that 7-MEOTA does not fall behind its more well-known parent compound - tacrine. Furthermore, we found, that 7-MEOTA exerts better properties in most of the test

Název v anglickém jazyce

A Resurrection of 7-MEOTA: A Comparison with Tacrine

Popis výsledku anglicky

Alzheimer's disease (AD) is a progressive neurodegenerative dementia which currently represents one of the biggest threats for the human kind. The cure is still unknown and various hypotheses (cholinergic, amyloidal, oxidative, vascular etc.) are investigated in order to understand the pathophysiology of the disease and on this basis find an effective treatment. Tacrine, the first approved drug for the AD disease treatment, has been reported to be a multitargeted drug, however it was withdrawn from themarket particularly due to its hepatotoxicity. Its derivative 7-methoxytacrine (7-MEOTA) probably due to the different metabolization does not exert this side effect. The aim of our study was to compare these two cholinesterase inhibitors from various, mainly cholinergic, points of view relevant for a potential AD drug. We found that 7-MEOTA does not fall behind its more well-known parent compound - tacrine. Furthermore, we found, that 7-MEOTA exerts better properties in most of the test

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Alzheimer Research

ISSN

1567-2050

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

AE - Spojené arabské emiráty

Počet stran výsledku

14

Strana od-do

893-906

Kód UT WoS článku

000324864400011

EID výsledku v databázi Scopus

—